Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise.
Stenlöf K, Cefalu WT, Kim KA, Alba M, Usiskin K, Tong C, Canovatchel W, Meininger G. · 2013
Read Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. by Stenlöf K, Cefalu WT, Kim KA, Alba M, Usiskin K, Tong C, Canovatchel W, Meininger G. (2013) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc3593184.txt.
Introduction
Klas Stenlöf and colleagues tested a new diabetes drug, canagliflozin, in Diabetes, Obesity and Metabolism in 2013. The drug blocks a kidney transporter that normally recaptures sugar from urine, so more sugar leaves the body and blood sugar falls. The phase 3 trial enrolled 584 adults with type 2 diabetes whose diet and exercise alone were not controlling their blood sugar. It assigned them to one of two daily doses or a dummy pill for twenty-six weeks.
Both doses beat placebo on the headline measure: hemoglobin A1c, a three-month sugar average, fell by 0.77 and 1.03 percentage points against a slight rise on placebo. Fasting and after-meal sugar, body weight, and systolic blood pressure also fell, while protective HDL cholesterol rose. Side effects were modestly more common on the drug, notably genital yeast infections and urine-related complaints, with few dropouts. The results position the drug as a workable single therapy.
Catalog record
| CREATOR | Stenlöf K, Cefalu WT, Kim KA, Alba M, Usiskin K, Tong C, Canovatchel W, Meininger G. |
|---|---|
| YEAR | 2013 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 41 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise By K Stenlöf, W T Cefalu, K-A Kim, M Alba, K Usiskin, C Tong, W Canovatchel, G Meininger Published in: Diabetes, Obesity & Metabolism DOI: 10.1111/dom.12054 ABSTRACT Abstract Aims Canagliflozin is a sodium glucose co-transporter 2 inhibitor in development for type 2 diabetes mellitus (T2DM). The efficacy and safety of canagliflozin were evaluated in subjects with T2DM inadequately controlled with diet and exercise. Methods In this 26-week, randomized, double-blind, placebo-controlled, phase 3 trial, subjects (N = 584) received canagliflozin 100 or 300 mg or placebo once daily. Primary endpoint was the change from baseline in haemoglobin A1c (HbA1c) at week 26. Secondary endpoints included the proportion of subjects achieving HbA1c < 7.0%; change from baseline in fasting plasma glucose (FPG), 2-h postprandial glucose (PPG) and systolic blood pressure (BP); and percent change in body weight, high-density lipoprotein cholesterol (HDL-C) and triglycerides. Adverse events (AEs) were recorded throughout the study. Results At week 26, HbA1c was significantly reduced from baseline with canagliflozin 100 and 300 mg compared with placebo (−0.77, −1.03 and 0.14%, respectively; p < 0.001 for both). Both canagliflozin doses significantly decreased FPG, 2-h PPG, body weight and systolic BP (p < 0.001 for all), and increased HDL-C compared with placebo (p < 0.01 for both). Overall incidences of AEs were modestly higher with canagliflozin versus placebo; rates of serious AEs and AE-related discontinuations were low and similar across groups. Incidences of genital mycotic infections, urinary tract infections and osmotic diuresis-related AEs were higher with canagliflozin; these led to few discontinuations. The incidence of hypoglycaemia was low across groups. Conclusion Canagliflozin treatment improved glycaemic control, reduced body weight and was generally well tolerated in subjects with T2DM inadequately controlled with diet and exercise. Keywords: phase 3 study, SGLT2 inhibitor, type 2 diabetes INTRODUCTION The substantial increase in the incidence of type 2 diabetes mellitus (T2DM) over the past decade is associated with a marked increase in the prevalence of obesity, which contributes greatly to insulin resistance, a key pathophysiologic parameter observed especially in individuals at risk. Given the role of obesity and sedentary lifestyles in contributing to the progression of T2DM, the first step in T2DM management is lifestyle change, exercise and weight loss; unfortunately, such interventions are often inadequate or short-lived in effectiveness. When non-pharmacological treatment fails, treatment with an antihyperglycaemic agent (AHA), often metformin, is initiated [1]. Metformin provides effective control, although some patients do not tolerate metformin due to gastrointestinal side-effects or have contraindications to the use of this agent, such as renal insufficiency. Type 2 diabetes is a progressive disease; initially, inadequate β-cell compensation for the increased demand in insulin due to insulin resistance precipitates hyperglycaemia; subsequent deterioration in β-cell function (βCF) and mass underlies the progression from non-pharmacological treatment through monotherapy failure, to the need for combination treatments [1–4]. Current oral AHA classes often do not provide sufficiently effective or durable glycaemic control with improved βCF; although metformin provides modest weight reduction, most oral agents lead to weight gain or are weight neutral, but do not substantively reduce body weight [1,5]. The recent American Diabetes Association/European Association for the Study of Diabetes position statement suggests that therapy should be individualized and tailored to the specific needs of each patient [1]. Therefore, there is a need for new AHAs that can provide long-term glycaemic control and additional benefits such as minimal hypoglycaemia and favourable effects on weight. Sodium glucose co-transporter 2 (SGLT2) inhibitors are a class of AHAs in development that have a mechanism of action different from those of current therapies, with a primary effect on renal glucose handling. Specifically, induction of urinary glucose excretion (UGE) via inhibition of renal glucose reabsorption by SGLT2 provides an insulin-independent mechanism for lowering blood glucose and improving glycaemic control [6]. Under normal conditions, almost all filtered glucose is reabsorbed until the filtered load exceeds the glucose resorptive capacity. The plasma glucose concentration at which renal resorptive capacity is exceeded and UGE occurs is called the renal threshold for glucose (RTG). Renal glucose resorptive capacity is increased in T2DM, contributing to the worsening of hyperglycaemia [7]. Canagliflozin, an SGLT2 inhibitor in development for the treatment of T2DM, lowers the RTG (range of 4.4–5.0 mmol/l), thereby increasing UGE and resulting in decreased plasma glucose, a mild osmotic diuresis and increased caloric loss (4 kcal/g of glucose), with a low potential for hypoglycaemia [8–13]. The loss of glucose with attendant caloric loss contributes to weight loss; in addition, improvements in βCF have been seen [8,11]. This clinical profile suggests that canagliflozin might be a useful therapeutic agent to treat patients with T2DM from early in the disease, as monotherapy, to later in the disease, in combination treatments. This 26-week, phase 3, CANagliflozin Treatment And Trial Analysis – Monotherapy (CANTATA-M) study evaluated the efficacy and safety of canagliflozin compared with placebo in subjects with T2DM inadequately controlled with diet and exercise. MATERIALS AND METHODS Subjects and Study Design This randomized, double-blind, placebo-controlled, phase 3 study was conducted in 17 countries (ClinicalTrials.gov identifier: NCT01081834). The study included both subjects with inadequate control on diet and exercise and subjects on an AHA, who underwent a washout of the agent. Subjects not on an AHA directly entered a 2-week, single-blind, placebo run-in period (week −2 to day 1), while subjects on an AHA underwent an 8-week, AHA washout/diet and exercise period followed by the placebo run-in period. After the placebo run-in period, all subjects were randomized into a 26-week, double-blind, placebo-controlled, core treatment period, followed by a 26-week, double-blind extension period. This publication reports the results of the 26-week core treatment period. Eligible subjects were men and women 18–80 years of age with T2DM who met one of the two following criteria: (i) not on an AHA at screening with haemoglobin A1c (HbA1c) ≥7.0 and ≤10.0% or (ii) on AHA monotherapy [except peroxisome proliferator-activated receptor-γ (PPARγ) agonist] or metformin plus sulfonylurea combination therapy (at ≤50% of maximally or near-maximally effective doses) with HbA1c ≥6.5 and ≤9.5% at screening and HbA1c ≥7.0 and ≤10.0% and fasting plasma glucose (FPG) <15.0 mmol/l at week −2. For subjects with HbA1c values above the inclusion range (HbA1c ≥7.0 and ≤10.0%), a substudy was conducted to assess the efficacy in elevated glycaemic states. Subjects were eligible to participate in the high glycaemic substudy if they had HbA1c >10.0 and ≤12.0% at screening or week −1 and FPG ≤19.4 mmol/l at week −1. Subjects eligible for this substudy entered a 1-week, single-blind, placebo run-in period followed by a 26-week, double-blind, active-treatment period. Given the poorer glycaemic control, all subjects received active treatment with canagliflozin 100 or 300 mg; double-blinding was to the dose of canagliflozin. Subjects in the high glycaemic substudy were not eligible for the 26-week extension period. In this report, the placebo-controlled study component will be referred to as the ‘main study’. Subjects were excluded if they had repeated FPG measurements >15.0 mmol/l during the pre-treatment phase (or >19.4 mmol/l for the high glycaemic substudy); a history of type 1 diabetes, hereditary glucose-galactose malabsorption, primary renal glucosuria or cardiovascular (CV) disease (including myocardial infarction, unstable angina, revascularization procedure or